The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
As therapeutic trials target early stages of Parkinson’s disease (PD), appropriate patient selection based purely on clinical criteria poses significant challenges. Members of the Critical Path for Parkinson’s Consortium formally submitted documentation to the European Medicines Agency (EMA) supporting the use of Dopamine Transporter (DAT) neuroimaging in early PD. Regulatory documents included a comprehensive literature review, a proposed analysis plan of both observational and clinical trial data, and an assessment of biomarker reproducibility and reliability. The research plan included longitudinal analysis of the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) and the Parkinson’s Progression Markers Initiative (PPMI) study to estimate the degree of enrichment achieved and impact on future trials in subjects with early motor PD. The presence of reduced striatal DAT binding based on visual reads of single photon emission tomography (SPECT) scans in early motor PD subjects was an independent predictor of faster decline in UPDRS Parts II and III as compared to subjects with scans without evidence of dopaminergic deficit (SWEDD) over 24 months. The EMA issued in 2018 a full Qualification Opinion for the use of DAT as an enrichment biomarker in PD trials targeting subjects with early motor symptoms. Exclusion of SWEDD subjects in future clinical trials targeting early motor PD subjects aims to enrich clinical trial populations with idiopathic PD patients, improve statistical power, and exclude subjects who are unlikely to progress clinically from being exposed to novel test therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig.2 The proportion of subjects with absence of DAT deficit in clinical trials increases with earlier stages of PD. A number of PD clinical studies have identified subjects defined as SWEDD by employing DAT imaging at baseline and follow up. The proportion of subjects defined as SWEDD decreases with the time since diagnosis for those in specific PD clinical studies targeting early stages of the disease. The proportion of SWEDD subjects is lower in studies enrolling subjects with longer duration of disease. As sponsors enroll PD subjects earlier in the disease (i.e., sooner after diagnosis), the value (benefit) of DAT imaging for enrichment increases. References for PD clinical studies: [38, 39, 41, 59– 61]. ELLDOPA: Levodopa; PRECEPT: Mixed Lineage Kinase Inhibitor CEP 1347; REAL-PD: Ropinirole; CALM-PD: Pramipexole; GPI1485: Immunophilin; PPMI: Parkinson’s Progression Markers Initiative.](https://figures.cochat.ai/paper-figures/c67f8a2c856f42f3908b4d598270846f/the-qualification-of-an-enrichment-biomarker-for-clinical-trials-targeting-early-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005 · cited 1×
“Novel therapeutic development efforts are underway targeting -synuclein [11] and the two most common genetic causes of PD, glucocerebrosidase (GBA) deficiency [12], and mutated forms of leucine rich repeat kinase 2 (LRRK2) [4, 13].”
BackgroundThe Emerging Evidence of the Parkinson Pandemic
Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-181474 · Cited by 1,977 · cited 1×
“Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting 2% to 3% of people over 65 years of age [1] and has been recently reported to be the most rapidly growing neurological disease [2, 3].”
BackgroundThe Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
Self-citationDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?
Reeve, A., Simcox, E., & Turnbull, D. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.004 · Cited by 947 · cited 1×
“Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting 2% to 3% of people over 65 years of age [1] and has been recently reported to be the most rapidly growing neurological disease [2, 3].”
BackgroundAccuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis
Rizzo, G., Copetti, M., Arcuti, S., Martino, D., Fontana, A., & Logroscino, G. (2016) · Neurology · doi:10.1212/wnl.0000000000002350 · Cited by 870 · cited 1×
“It can, however, be challenging to diagnose PD, especially in early stage disease when other neurological disorders can present with similar signs and symptoms [16, 17].”
BackgroundSlower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Benamer, H. T. S., Patterson, J., Grosset, D. G., Booij, J., de Bruin, K., van Royen, E., Speelman, J. D., Horstink, M. H. I. M., Sips, H. J. W. A., Dierckx, R. A., et al. (2000) · Movement Disorders · doi:10.1002/1531-8257(200005)15:3<503::aid-mds1013>3.0.co;2-v · Cited by 707 · cited 1×
“Reductions of DAT radiotracer binding (DAT deficit) correlate with the disease duration from early stages of the disease [34], matching pathological findings from DAT immunohistochemistry [35].”
BackgroundSelf-citation
Research works printed but not linked: 2
- Marek K, 2003, Adv Neurol, 91, 183
- Abi-Dargham A, 1996, J Nucl Med, 37, 1129
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Prange, S., Klinger, H., Laurencin, C., Danaila, T., & Thobois, S. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00942-1 · Cited by 167
“These developments will prove instrumental for the recognition of imaging biomarkers specific to PD depression, which may in turn serve as enrichment biomarkers in clinical trials [313].”
BackgroundThe Parkinson Study Group SURE-PD3 Investigators, Bluett, B., Togasaki, D. M., Mihaila, D., Evatt, M., Rezak, M., Jain, S., Schwarzschild, M. A., Ascherio, A., Casaceli, C., et al. (2021) · JAMA · doi:10.1001/jama.2021.10207 · Cited by 165
Self-citationBiomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 88
“It can limit inclusion of people who are symptomatic without evidence of dopamine degeneration (SWEDD), a group that comprises approximately 15% of cases when using clinical criteria alone 81,82 .”
Stephenson, D., Alexander, R., Aggarwal, V., Badawy, R., Bain, L., Bhatnagar, R., Bloem, B. R., Boroojerdi, B., Burton, J., Cedarbaum, J. M., et al. (2020) · Digital Biomarkers · doi:10.1159/000512500 · Cited by 63
Self-citationLifestyle Interventions for the Prevention of Parkinson Disease: A Recipe for Action
Daalen, J. M. J., Schootemeijer, S., Richard, E., Darweesh, S. K. L., & Bloem, B. R. (2022) · Neurology · doi:10.1212/wnl.0000000000200787 · Cited by 72
“Other Considerations Having a sedentary lifestyle could be included as enrichment factor, thus ascertaining inclusion of a subgroup with a putatively higher-than-average PD risk and one that is perhaps more likely to benefit from an increase in physical activity levels.(23) A challenge is that particularly those with…”
BackgroundApproaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned
Hung, A. Y., & Schwarzschild, M. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00964-w · Cited by 54
“To improve subject selection, DAT imaging is now being used as an enrichment biomarker for clinical trials targeting early PD [98].”
MethodThe meaning of significant mean group differences for biomarker discovery
Loth, E., Ahmad, J., Chatham, C., López, B., Carter, B., Crawley, D., Oakley, B., Hayward, H., Cooke, J., San José Cáceres, A., et al. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009477 · Cited by 52
“Recent interest in biomarker discovery has been sparked by their successful clinical use in multiple areas of medicine [8], to aid in more objective and reliable diagnosis of a condition, or in predicting individual treatment response [9].”
BackgroundConrado, D. J., Nicholas, T., Tsai, K., Macha, S., Sinha, V., Stone, J., Corrigan, B., Bani, M., Muglia, P., Watson, I. A., et al. (2018) · Clinical and Translational Science · doi:10.1111/cts.12492 · Cited by 49
Self-citationArtificial intelligence for dementia drug discovery and trials optimization
Doherty, T., Yao, Z., Khleifat, A. A. L., Tantiangco, H., Tamburin, S., Albertyn, C., Thakur, L., Llewellyn, D. J., Oxtoby, N. P., Lourida, I., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13428 · Cited by 48
“12,13 A recent study has found that drug targets with genetic support were twice as likely to improve approval likelihood of a new drug candidate at early-stage clinical trials.”
Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders
Wallert, E. D., van de Giessen, E., Knol, R. J. J., Beudel, M., de Bie, R. M. A., & Booij, J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263197 · Cited by 49
Autophagic- and Lysosomal-Related Biomarkers for Parkinson’s Disease: Lights and Shadows
Xicoy, H., Peñuelas, N., Vila, M., & Laguna, A. (2019) · Cells · doi:10.3390/cells8111317 · Cited by 43
Chen, J.-F., & Schwarzschild, M. A. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.10.024 · Cited by 39
Open Data Revolution in Clinical Research: Opportunities and Challenges
Shahin, M. H., Bhattacharya, S., Silva, D. S., Kim, S., Burton, J. K., Podichetty, J. T., Romero, K., & Conrado, D. J. (2020) · Clinical and Translational Science · doi:10.1111/cts.12756 · Cited by 38
Self-citationEffective Data Sharing as a Conduit for Advancing Medical Product Development
Karpen, S. R., White, J. K., Mullin, A. P., O’Doherty, I. M., Hudson, L. D., Romero, K., Sivakumaran, S., Stephenson, D. T., Turner, E. C., & Larkindale, J. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-020-00255-8 · Cited by 39
“This biomarker has been qualified through EMA’s Qualification of Novel Methodologies for use in Clinical Trials program [23].”
MethodSelf-citationAntonini, A., Bravi, D., Sandre, M., & Bubacco, L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1771693 · Cited by 33
Neurofilament light chain level in plasma extracellular vesicles and Parkinson’s disease
Chung, C., Chan, L., Chen, J., Bamodu, O. A., & Hong, C. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420975917 · Cited by 34
Lanfranchi, F., Arnaldi, D., Miceli, A., Mattioli, P., D’Amico, F., Raffa, S., Donegani, M. I., Chiola, S., Massa, F., Pardini, M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06069-0 · Cited by 29
Dopamine transporter imaging in neurodegenerative movement disorders: PET vs. SPECT
Kerstens, V. S., & Varrone, A. (2020) · Clinical and Translational Imaging · doi:10.1007/s40336-020-00386-w · Cited by 27
Molecular Imaging in Parkinsonian Disorders—What’s New and Hot?
Prange, S., Theis, H., Banwinkler, M., & van Eimeren, T. (2022) · Brain Sciences · doi:10.3390/brainsci12091146 · Cited by 25
“Moreover, molecular imaging has the potential to serve both as an enrichment and progression biomarker, in particular in prodromal patients, critical for efficient design in disease-modification trials [73,205].”
BackgroundSimuni, T., Merchant, K., Brumm, M. C., Cho, H., Caspell‐Garcia, C., Coffey, C. S., Chahine, L. M., Alcalay, R. N., Nudelman, K. N. H., Foroud, T., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00404-w · Cited by 20
Self-citationHutchison, R. M., Evans, K. C., Fox, T., Yang, M., Barakos, J. A., Bedell, B. J., Cedarbaum, J. M., Bryś, M., Siderowf, A. D., & Lang, A. E. (2021) · BMC Neurology · doi:10.1186/s12883-021-02470-8 · Cited by 19
“Of note, the SWEDD percentage varies by the average disease duration of recruited participants [10, 25].”
BackgroundSelf-citationBrumberg, J., Kerstens, V. S., Cselényi, Z., Svenningsson, P., Sundgren, M., Fazio, P., & Varrone, A. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20958755 · Cited by 18
“However, all evaluated SBRs agreed with the reference BPND by identifying the SWEDD patient as outlier in the PD cohort, which also supports the suitability of [(18)F]-FE-PE2I PET for patient selection in clinical trials.(12)”
BackgroundResultArnaldi, D., Famà, F., Girtler, N. G., Brugnolo, A., Pardini, M., Mattioli, P., Meli, R., Massa, F., Orso, B., Sormani, M. P., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14664 · Cited by 17
“The GLM analysis yielded a significant interaction between the effect of group, time, and regions (F[1,27] = 9.”
MethodSeckin, Z. I., Whitwell, J. L., Utianski, R. L., Botha, H., Ali, F., Duffy, J. R., Clark, H. M., Machulda, M. M., Jordan, L. G., Min, H.-K. P., et al. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09883-4 · Cited by 15
GLP-1 agonists to slow down Parkinson’s progression? The quest continues
Bloem, B. R., Macklin, E. A., & Schwarzschild, M. A. (2025) · Med · doi:10.1016/j.medj.2025.100645 · Cited by 16
Seibyl, J. P. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264773 · Cited by 18
Self-citationBrumberg, J., Schröter, N., Blazhenets, G., Omrane, M. A., Volz, C., Weiller, C., Rijntjes, M., Frings, L., Hellwig, S., Jost, W. H., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268956 · Cited by 11
Zhang, J., Campion, S. N., Catlin, N. R., Reagan, W. J., Palyada, K., Ramaiah, S. K., & Ramanathan, R. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03460-0 · Cited by 11
Stephenson, D. T., Ollivier, C., Brinton, R. D., & Barrett, J. S. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2528 · Cited by 13
Self-citationPharmacometrics: The Already-Present Future of Precision Pharmacology
Bandeira, L. C., Pinto, L., & Carneiro, C. M. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00439-4 · Cited by 12
Clarkson, R. D. O., Jabbour, M., Pelayo, D. A., Lara, D., Croix, S. L., Mumman, M., Stukas, S., Anderson, R., Meraz, D., Bangura, A., et al. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111155 · Cited by 8
Dang, M., Liu, B., Chen, Y., & Zhang, Z. (2026) · Psychoradiology · doi:10.1093/psyrad/kkag007 · Cited by 10
Beyond Alzheimer’s disease—translating biomarker insights across CNS diseases
Brady, L. S., Mahinrad, S., Edelmayer, R. M., Potter, W. Z., Hutten, S. J., Anticevic, A., Taylor‐Burds, C., Winston, C. N., Coetzee, T., Paulsen, J. S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adr2511 · Cited by 9
Reliability and validity of visual analysis of [18F]FE-PE2I PET/CT in early Parkinsonian disease
af Bjerkén, S., Axelsson, J., Larsson, A., Flygare, C., Remes, J., Strandberg, S., Eriksson, L., Bäckström, D. C., & Mo, S. J. (2023) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001679 · Cited by 6
Pauley, M., Henscheid, N., David, S. E., Karpen, S. R., Romero, K., & Podichetty, J. T. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2976 · Cited by 6
“CPath has previously developed Graphical User Interfaces (GUIs) for Clinical Trial Enrichment (CTE) and Clinical Trial Simulation to expand access to disease progression models.(11) These tools have proved to be valuable for scientists and clinicians from all backgrounds, for trial- specific enrichment and stratificat…”
MethodSelf-citationNeuroimaging Biomarkers in Parkinson’s Disease
Holmes, S. E., & Tinaz, S. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69491-2_21 · Cited by 6
Conrado, D. J., Burton, J. K., Hill, D., Willis, B. A., Sinha, V. P., Stone, J. A., Coello, N., Wang, W., Chen, D. Z., Nicholas, T., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1766 · Cited by 4
Self-citationThe Utility of Biomarkers for Assessment and Intervention in Neurodevelopmental Disorders
Guldner, S., Ernst, J., Nees, F., & Holz, N. E. (2024) · Integrated science · doi:10.1007/978-3-031-76414-1_3 · Cited by 3
Leveraging the regulatory framework to facilitate drug development in Parkinson's disease
Müller, M. L. T. M., & Stephenson, D. T. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00015-1 · Cited by 2
Self-citationA case study exploration of Parkinson's disease
Mark, J., & Mortimore, G. (2024) · International Journal for Advancing Practice · doi:10.12968/ijap.2024.2.1.20 · Cited by 1
Yilmaz, B., Sengupta, S. K., Szidonya, L. K., Yusufaly, T., Panchal, R., Yaylali, I., Litvan, I., & Obrzut, S. L. (2025) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001830 · Cited by 1
Stephenson, D. T., Concha‐Marambio, L., Lanz, T. A., Merchant, K., Brockmann, K., King, N. M. P., Carrillo, L., Pedata, A., Kocherla, H., & Hutten, S. J. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261463936 · Cited by 1
Self-citationTsakalozou, E., Fang, L., Skoda, E., Nicholas, T., Kollipara, S., Ren, K., Grosser, S. C., Rege, B. D., Roy, P., Zhu, H., et al. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03839-x
“This platform was presented for qualification to the EMA, and while the CHMP did provide a letter of support, further validation was encouraged [34].”
Self-citationAntonini, A., Gross, R. E., Leon, M. D., Kwok, K., Foltynie, T., Höglinger, G. U., Gasser, T., Corvol, J., Pedrosa, D. J., Volkmann, J., et al. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261481704
Metadata
- Authors
- Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., Nicholas, T., Matthews, D., Xie, Z., Imam, S., Maguire, P., Russell, D., Gordon, M. F., Stebbins, G. T., Somer, E., Gallagher, J., Roach, A., Basseches, P., Grosset, D., Marek, K., & on behalf of the Critical Path for Parkinson’s Consortium
- Affiliations
- Critical Path Institute (US)
- University College London, UK
- Biogen (United States) (US)
- European Medicines Agency (NL)
- Parkinson's UK (GB)
- Institute for Neurodegenerative Disorders (US)
- Denali Therapeutics (United States) (US)
- Pfizer (United States) (US)
- Archer Daniels Midland (United States) (US)
- National Center for Toxicological Research (US)
- UCB, Brussels, Belgium
- CPP Scientific Advisor, PA, USA
- Rush University (US)
- GE Healthcare, London, UK
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Glasgow (GB)
- Corresponding author
- Stephenson, Diane
- ORCID
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2019-07-08
- Volume
- 9
- Issue
- 3
- Pages
- 553-563
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- PMC
- PMC6700608
- OpenAlex
- W2958884967
- Cited by
- 46
- References
- 57
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 5 · 2020: 11 · 2019: 1
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Parkinson s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Parkinson's Disease Foundation
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Davis Phinney Foundation
- Strong
- Parkinson's UK
- University of Oxford
- Newcastle University
- University of Glasgow
- Radboud Universiteit
- H. Lundbeck A/S
- U.S. Food and Drug Administration (U18FD005320)
- Merck Sharp and Dohme
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, dopamine transporter SPECT, patient selection, European Medicines Agency, Parkinson's Progression Markers Initiative, dopaminergic deficit, trial enrichment, statistical power
- MeSH terms
- Clinical Studies as Topic, Clinical Trials as Topic, Corpus Striatum, Humans, Parkinson Disease, Societies, Medical, Biomarkers, Tomography, Emission-Computed, Single-Photon, Dopamine Plasma Membrane Transport Proteins, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.